Todd E Golde

Todd E Golde

Professor, Director McKnight Brain Institute

Business Phone: (352) 273-9456
Business Email:

About Todd E Golde

Todd E. Golde, M.D., Ph.D., is director of the Evelyn F. and William L. McKnight Brain Institute (MBI) of the University of Florida, where he oversees, champions and facilitates neuroscience and neuromedicine research programs across the UF campus. A professor of neuroscience and neurology, Dr. Golde joined the UF faculty in 2009 and became founding director of UF’s Center for Translational Research in Neurodegenerative Disease (CTRND), which he led until taking the helm at the MBI in December 2016.

An internationally known expert in the scientific understanding of Alzheimer’s disease (AD), Dr. Golde has published more than 290 papers that have been cited more than 36,000 times. Over time his research has taken on a more transnational focus. He currently directs i) the NIH funded 1Florida Alzheimer’s Disease Research Center (ADRC, that focuses on early detection and markers of progression in in diverse populations (especially Hispanics an African Americans) ii) a consortium U01 under the NIH’s accelerating medicine partnership AD program (AMP-AD) designed to identify novel targets in the immune systems in AD iii) studies exploring a novel immunotherapy targeting the HPA axis in AD , iv) the use of a novel brain slice culture model of tauopathy and α-synucleinopathy to identify therapeutic targets for the proteinopathies and the dysfunction that they cause, and v) an gene therapy approach to treating trigmenal neuralgia. Underlying his laboratory’s wet-bench research studies is the development of an extensive rAAV vector “toolkit” that enables us to accelerate translational preclinical studies that can help advance therapeutic discovery in many disease settings.

In addition to his research and intramural administrative activities, in recent years Dr. Golde has been an active advocate for AD and neurodegenerative disease research at the state, national and international levels. At the national level, he has served on the medical and scientific advisory board for the National Alzheimer’s Association and he continue to do so for the Bright Focus Foundation. At the state level, he has served on several advisory boards relating to AD, and has worked to secure state support for Alzheimer’s research at UF as well as implement a statewide grants program to support AD research. Through his scientific reviews and presentations at national and international conferences, he not only discuss scientific advances, but also highlight the many challenges that we face in combating the AD epidemic (see, for example, Golde et al Alz Res & Therapy 2011, Golde et al Neuron 2011, Golde J. Neurochemistry 2016, Golde et al. Science 2018, Dawson et al Nature Neuroscience 2018, Golde, Neuron 2019).


Director of the Evelyn F. and William L. McKnight Brain Institute
2017-current · University of Florida
Alzheimer's Research UK Drug Discovery Institutes Advisory board
2016-current · ARUK
Co-Organizer EMBO Conferences on Neurodegenerative disease
2015-2017 · EMBO
Faculty Research Award Basic Science
2014 · UF College of Medicine
Medical and Scientific Advisory Council for the National Alzheimer’s Association
2012-2019 · National Alzheimer's Assocaition
Purple Ribbon Task Force for Alzheimer’s Disease
2012-2013 · Florida Speaker of the House of Representatives Appointment
Alzheimer’s Disease Advisory Committee (ADI)
2010-2016 · State of Florida, Department of Elder Affairs, Governor's Appointment
Founding Director, Center for Translational Research in Neurodegenerative disease
2010-2016 · University of Florida
Met Life Award for Medical Research
2010 · Met Life Foundation
Stephen DeArmond Lecturer
2010 · American Association of Neuropathology
Thome Award in Alzheimer's Disease Drug Discovery Research
2010 · Edward N. and Della L. Thome Memorial Foundation
Founding Co-Editor in Chief – Alzheimer’s Research and Therapy
2009-2019 · BMC
Consulting Editor – Journal of Clinical Investigator
2007-Current · American Society for Clinical Investigation
Coins for Alzheimer's Research Trust
2007 · Rotary Clubs of America
BrightFocus Foundation Alzheimer’s Advisory Board
2006-Current · BrightFocus Foundation
Chair , Department of Neuroscience
2003-2009 · Mayo Clinic Florida
Outstanding Contributor, Alzheimer’s Research Forum
2001 · Alzheimer's Research Forum
Graduate Education Coordinator, Mayo Clinic Florida
1999-2003 · Mayo Clinic
Ellison Medical Foundation New Scholar
1998 · Ellison Medical Foundation
Paul Beeson Physician Faculty Scholar
1997 · American Federation for Aging Research
Zenith Award
1995 · Alzheimer’s Association
Experimental Pathologist-in-Training Award
1993 · American Society for Investigative Pathology
The Oscar E. Schotte Award, Awarded to a senior student for the outstanding Honor's thesis in the Department of Biology.
1985 · Amherst College

Research Profile

CONTRIBUTIONS TO SCIENCE 1. As a MD PhD student and postdoc with Dr. Steven Younkin, I played a pivotal role in studies showing that the amyloid beta protein (Abeta) was a normal metabolite and that mutations that cause AD alter Abeta production in a manner that promote Abeta aggregation. These studies provided pivotal support for the Abeta aggregate (amyloid) hypothesis of AD and enabled drug discovery programs aimed at altering Abeta accumulation. a) Golde TE, Estus S, Younkin LH, Selkoe DJ, Younkin SG. Processing of the amyloid protein precursor to potentially amyloidogenic derivatives. Science. 1992;255(5045):728-30. doi: 10.1126/science.1738847. PubMed PMID: 1738847. b) Shoji M*, Golde TE*, Ghiso J, Cheung TT, Estus S, Shaffer LM, Cai XD, McKay DM, Tintner R, Frangione B. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science. 1992;258(5079):126-9. doi: 10.1126/science.1439760. PubMed PMID: 1439760.. c) Cai XD, Golde TE, Younkin SG. Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. Science. 1993;259(5094):514-6. doi: 10.1126/science.8424174. PubMed PMID: 8424174. d) Suzuki N, Cheung TT, Cai XD, Odaka A, Otvos L, Eckman C, Golde TE, Younkin SG. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science. 1994;264(5163):1336-40. doi: 10.1126/science.8191290. PubMed PMID: 8191290. 2. In studies conducted in collaboration with Dr. Edward Koo’s laboratory (UCSD), we demonstrated that select non-steroidal anti-inflammatory agents (NSAIDs) could modulate Abeta42 production and that this effect was attributable to direct alteration of gamma-secretase activity. Subsequently we identified compounds that lowered Abeta42 but lacked cyclooxygenase activity, we also described compounds with the opposite effect that raise Aβ42 levels, and finally that these compounds work in part by targeting substrate. These data and modeling studies on the biological properties of “short” Aβ peptides has supported the rationale for development and testing of what are now referred to as gamma-secretase modulators (GSMs) as potential therapeutics for AD. a) Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature. 2001;414(6860):212-6. doi: 10.1038/35102591. PubMed PMID: 11700559. b) Kukar T, Murphy MP, Eriksen JL, Sagi SA, Weggen S, Smith TE, Ladd T, Khan MA, Kache R, Beard J, Dodson M, Merit S, Ozols VV, Anastasiadis PZ, Das P, Fauq A, Koo EH, Golde TE. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nat Med. 2005;11(5):545-50. Epub 2005/04/17. doi: 10.1038/nm1235. PubMed PMID: 15834426. c) Kukar TL, Ladd TB, Bann MA, Fraering PC, Narlawar R, Maharvi GM, Healy B, Chapman R, Welzel AT, Price RW, Moore B, Rangachari V, Cusack B, Eriksen J, Jansen-West K, Verbeeck C, Yager D, Eckman C, Ye W, Sagi S, Cottrell BA, Torpey J, Rosenberry TL, Fauq A, Wolfe MS, Schmidt B, Walsh DM, Koo EH, Golde TE. Substrate-targeting gamma-secretase modulators. Nature. 2008;453(7197):925-9. doi: 10.1038/nature07055. PubMed PMID: 18548070; PMCID: PMC2678541. d) Moore BD, Martin J, de Mena L, Sanchez J, Cruz PE, Ceballos-Diaz C, Ladd TB, Ran Y, Levites Y, Kukar TL, Kurian JJ, McKenna R, Koo EH, Borchelt DR, Janus C, Rincon-Limas D, Fernandez-Funez P, Golde TE. Short Aβ peptides attenuate Aβ42 toxicity in vivo. J Exp Med. 2018;215(1):283-301. Epub 2017/12/05. doi: 10.1084/jem.20170600. PubMed PMID: 29208777; PMCID: PMC5748850.3. 3. A parallel area of interest to GSMs has been the therapeutic utility of targeting intramembrane cleaving proteases in a variety of indications. In 2002, in collaboration with Dr. Chris Ponting, we identified a family of intramembrane protease (presenilin homologs/signal peptide peptidases) that was related to gamma-secretase. In work conducted in collaboration with Drs. Osborne (UMASS), Miele (LSU/Tulane), and Greenbaum (U Penn), we have evaluated targeting these proteases in cancer, immunologic disease, and malaria. a) Ponting CP, Hutton M, Nyborg A, Baker M, Jansen K, Golde TE. Identification of a novel family of presenilin homologues. Hum Mol Genet. 2002;11(9):1037-44. doi: 10.1093/hmg/11.9.1037. PubMed PMID: 11978763. b) Das P, Verbeeck C, Minter L, Chakrabarty P, Felsenstein K, Kukar T, Maharvi G, Fauq A, Osborne BA, Golde TE. Transient pharmacologic lowering of Aβ production prior to deposition results in sustained reduction of amyloid plaque pathology. Mol Neurodegener. 2012;7:39. Epub 2012/08/14. doi: 10.1186/1750-1326-7-39. PubMed PMID: 22892055; PMCID: PMC3477045. c) R Harbut MB, Patel BA, Yeung BK, McNamara CW, Bright AT, Ballard J, Supek F, Golde TE, Winzeler EA, Diagana TT, Greenbaum DC. Targeting the ERAD pathway via inhibition of signal peptide peptidase for antiparasitic therapeutic design. Proc Natl Acad Sci U S A. 2012;109(52):21486-91. Epub 2012/12/11. doi: 10.1073/pnas.1216016110. PubMed PMID: 23236186; PMCID: PMC3535666. d) Ran Y, Hossain F, Pannuti A, Lessard CB, Ladd GZ, Jung JI, Minter LM, Osborne BA, Miele L, Golde TE. γ-Secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct. EMBO Mol Med. 2017;9(7):950-66. doi: 10.15252/emmm.201607265. PubMed PMID: 28539479; PMCID: PMC5494507. 4. My laboratory has been at the forefront of developing rAAV-based models and delivery of biotherapeutics to the brain, spinal cord and muscle. Much of this work has focused on delivery of potentially biotherapeutic molecules to models of Alzheimer’s disease. We continue to revise and update this technology, and our most recent study describes using minimally purified rAAV for both in vitro and ex vivo studies, which will enable rAAV technology to be much more accessible to the wider community. a) Levites Y, Jansen K, Smithson LA, Dakin R, Holloway VM, Das P, Golde TE. Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid beta40, and amyloid beta42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice. J Neurosci. 2006;26(46):11923-8. doi: 10.1523/JNEUROSCI.2795-06.2006. PubMed PMID: 17108166; PMCID: PMC6674861. b) Chakrabarty P, Rosario A, Cruz P, Siemienski Z, Ceballos-Diaz C, Crosby K, Jansen K, Borchelt DR, Kim JY, Jankowsky JL, Golde TE, Levites Y. Capsid serotype and timing of injection determines AAV transduction in the neonatal mice brain. PLoS One. 2013;8(6):e67680. Epub 2013/06/25. doi: 10.1371/journal.pone.0067680. PubMed PMID: 23825679; PMCID: PMC3692458. c) Ayers JI, Fromholt S, Sinyavskaya O, Siemienski Z, Rosario AM, Li A, Crosby KW, Cruz PE, DiNunno NM, Janus C, Ceballos-Diaz C, Borchelt DR, Golde TE, Chakrabarty P, Levites Y. Widespread and efficient transduction of spinal cord and brain following neonatal AAV injection and potential disease modifying effect in ALS mice. Mol Ther. 2015;23(1):53-62. Epub 2014/09/17. doi: 10.1038/mt.2014.180. PubMed PMID: 25228069; PMCID: PMC4426802. d) Goodwin MS, Croft CL, Futch HS, Ryu D, Ceballos-Diaz C, Liu X, Paterno G, Mejia C, Deng D, Menezes K, Londono L, Arjona K, Parianos M, Truong V, Rostonics E, Hernandez A, Boye SL, Boye SE, Levites Y, Cruz PE, Golde TE. Utilizing minimally purified secreted rAAV for rapid and cost-effective manipulation of gene expression in the CNS. Mol Neurodegener. 2020;15(1):15. Epub 2020/03/02. doi: 10.1186/s13024-020-00361-z. PubMed PMID: 32122372; PMCID: PMC7053119. 5. Over the last 10 years, my research has expanded into the area of innate immunity’s role in neurodegenerative disease. Recent work from my lab has challenged a long-standing hypothesis that inflammatory processes in AD accelerate Aβ deposition. Published studies also reveal a potential novel role of interferon-gamma in nigrostriatal degeneration and novel roles for decoy receptors in AD. We have now expanded these studies to broadly explore immune modulators as mediators of neurodegenerative pathways. a) Chakrabarty P, Jansen-West K, Beccard A, Ceballos-Diaz C, Levites Y, Verbeeck C, Zubair AC, Dickson D, Golde TE, Das P. Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition. FASEB J. 2010;24(2):548-59. Epub 2009/10/13. doi: 10.1096/fj.09-141754. PubMed PMID: 19825975; PMCID: PMC3083918. b) Chakrabarty P, Ceballos-Diaz C, Lin WL, Beccard A, Jansen-West K, McFarland NR, Janus C, Dickson D, Das P, Golde TE. Interferon-γ induces progressive nigrostriatal degeneration and basal ganglia calcification. Nat Neurosci. 2011;14(6):694-6. Epub 2011/05/15. doi: 10.1038/nn.2829. PubMed PMID: 21572432; PMCID: PMC3780582. c) Chakrabarty P, Li A, Ladd TB, Strickland MR, Koller EJ, Burgess JD, Funk CC, Cruz PE, Allen M, Yaroshenko M, Wang X, Younkin C, Reddy J, Lohrer B, Mehrke L, Moore BD, Liu X, Ceballos-Diaz C, Rosario AM, Medway C, Janus C, Li HD, Dickson DW, Giasson BI, Price ND, Younkin SG, Ertekin-Taner N, Golde TE. TLR5 decoy receptor as a novel anti-amyloid therapeutic for Alzheimer’s disease. J Exp Med. 2018;215(9):2247-64. doi: 10.1084/jem.20180484. PubMed PMID: 30158114; PMCID: PMC6122970. d) Chakrabarty P, Li A, Ceballos-Diaz C, Eddy JA, Funk CC, Moore B, DiNunno N, Rosario AM, Cruz PE, Verbeeck C, Sacino A, Nix S, Janus C, Price ND, Das P, Golde TE. IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior. Neuron. 2015;85(3):519-33. Epub 2015/01/22. doi: 10.1016/j.neuron.2014.11.020. PubMed PMID: 25619653; PMCID: PMC4320003.

Open Researcher and Contributor ID (ORCID)


Areas of Interest
  • Adeno-Associated Viral Gene Therapy
  • Alzheimer’s Disease
  • Cancer Therapeutics
  • Dementia
  • Immunoproteostasis
  • Neurodegenerative diseases
  • Neuroimmune interactions in Neurodegenerative diseases
  • Trigeminal Neuralgia
  • intramembrane cleaving proteases


2020 Proceedings of the National Academy of Sciences of the United States of America. Biological Sciences
2020 Acta Neuropathologica Communications
2019 Alzheimer's & dementia. Diagnosis, assessment & disease monitoring
2018 Journal of Experimental Medicine
2015 The Journal of Neuroscience
2014 Alzheimers Research & Therapy
2013 The FASEB's Journal
2013 Biochimica Et Biophysica Acta-Molecular Basis of Disease
2012 Alzheimers Research & Therapy
2011 Alzheimers Research & Therapy
2011 Alzheimers Research & Therapy
2010 Clinical Cancer Research
2009 Alzheimers Research & Therapy
2009 Proceedings of the National Academy of Sciences
2008 The Journal of Neuroscience
2007 The Journal of Neuroscience
2005 Nature Biotechnology
2003 Biochemical and Biophysical Research Communications
2000 Biochemical and Biophysical Research Communications


Aug 2020 ACTIVE
Interdisciplinary Training in Movement Disorders and Neurorestoration
Jun 2020 ACTIVE
1Florida Alzheimers Disease Research Center
NATL INST OF HLTH NIA · Principal Investigator
Sep 2019 ACTIVE
Modulation of Alzheimers disease by Herpes simplex virus infection
UNIV OF WASHINGTON · Principal Investigator
Aug 2019 ACTIVE
Elucidating factors that modulate tauopathy and cellular degeneration to guide therapeutic development
Aug 2019 ACTIVE
Immunotherapy targeting the HPA axis in Alzheimers disease
NATL INST OF HLTH NIA · Principal Investigator
Sep 2018 – Aug 2020
A Systems Approach to Targeting Innate Immunity in AD
NATL INST OF HLTH NIA · Principal Investigator
Jul 2018 ACTIVE
Understanding and Targeting Tau-induced Neurodegeneration
BRIGHTFOCUS FOU · Project Manager
Jun 2018 ACTIVE
APOE as a modifier of prion-like spread in dementia
Feb 2018 – Aug 2020
Periodontal Bacteria augment Progression of Abeta and Tau Pathology
Feb 2018 ACTIVE
Towards Understanding the Biological Role of Newly Discovered Alzheimers Disease Susceptibility Genes Affecting Immune Function
Sep 2017 ACTIVE
Immunotherapeutic Targeting of Corticotropin-Releasing Hormone in Alzheimers Disease
Sep 2017 – May 2018
APOE as a modifier of prion-like spread in dementia
Aug 2017 – Jul 2020
Periodontal bacteria and Alzheimers disease
Jan 2016 ACTIVE
Miscellaneous Donors (Dr. Golde)
MISCELLANEOUS DONORS · Principal Investigator
Aug 2015 ACTIVE
University of Florida – Mt. Sinai Medical Center AD Research Center
NATL INST OF HLTH NIA · Principal Investigator
Aug 2015 – Dec 2016
Exploring the positive effects of rAAV-IL-10 in a ALS mo
Jul 2015 ACTIVE
UNIV OF WASHINGTON · Principal Investigator
Jun 2015 – May 2017
rAAV based somatic sheep brain and spinal cord
UF DSR OPPORTUNITY FUND · Principal Investigator
May 2014 – Feb 2019
Immune-Mediated Mechanisms underlying CNS Abeta Clearance
NATL INST OF HLTH NIA · Principal Investigator
Sep 2013 – Aug 2019
Targeting Multiple Diseases Through Gamma Secretase
UNIV OF MASSACHUSETTS · Principal Investigator
Sep 2013 – Aug 2018
A Systems Approach to Targeting Innate Immunity in AD
NATL INST OF HLTH NIA · Principal Investigator
Jul 2010 ACTIVE
Therapeutic Discovery in Neurodegenerative Disease
FL CLINICAL PRACTICE ASSO · Principal Investigator


Published April 2010
Reducing Abeta42 Levels and Abeta Aggregation (MAYO CLINIC)
#2011/0021471 A1
Published June 2018
Compounds For Treating Neurodegenerative Proteinopathies (DIV)
Issued July 2018
Compounds for Treating Neurodegenerative Proteinopathies


Chief Resident Clinical Pathology and Laboratory Medicine
1995-1996 · University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania
Resident Clinical Pathology and Laboratory Medicine
1994-1996 · University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania
Postdoctoral Fellow, Neuroscience Training Grant
1991-1992 · Case Western Reserve Universit ; Mentor: Steven G. Younkin M.D., Ph.D.
Research Associate
1990-1991 · Institute of Pathology Case Western Reserve University; Mentor: Steven G. Younkin, M.D. Ph.D
MD PhD, NIH funded Medical Scientist Training Program (MSTP)
1985-1994 · Case Western Reserve University
1981-1985 · Amherst College

Contact Details

(352) 273-9456